Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 205,854,006 papers from all fields of science
Search
Sign In
Create Free Account
Doxorubicin
Known as:
Hydroxyldaunorubicin
, 5,12-Naphthacenedione, 10-((3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-, (8S-cis)-
, Doxorubicin [Chemical/Ingredient]
Expand
An anthracycline antibiotic with antineoplastic activity. Doxorubicin, isolated from the bacterium Streptomyces peucetius var. caesius, is the…
Expand
National Institutes of Health
Create Alert
Alert
Related topics
Related topics
48 relations
AC-T Regimen
CDE protocol-cyclophosphamide/doxorubicin/etoposide
CHVmP-VB protocol
COPP-ABV Regimen
Expand
Narrower (20)
ACP protocol
CHOP protocol-cyclophosphamide/doxorubicin/prednisone/vincristine
CISCA protocol
DOXO-cell
Expand
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
Review
2013
Review
2013
Doxorubicin: an update on anticancer molecular action, toxicity and novel drug delivery systems
Oktay Tacar
,
P. Sriamornsak
,
C. Dass
The Journal of pharmacy and pharmacology
2013
Corpus ID: 34737360
Objectives The frontline drug doxorubicin has been used for treating cancer for over 30 years. While providing a cure in select…
Expand
Review
2005
Review
2005
Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials
O. Abe
,
R. Abe
,
+332 authors
L. Martino
The Lancet
2005
Corpus ID: 7427749
Highly Cited
2003
Highly Cited
2003
Congestive heart failure in patients treated with doxorubicin
S. Swain
,
F. Whaley
,
M. Ewer
Cancer
2003
Corpus ID: 37511219
Doxorubicin is a highly effective and widely used cytotoxic agent with application that is limited by cardiotoxicity related to…
Expand
Highly Cited
2001
Highly Cited
2001
Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.
D. Slamon
,
B. Leyland-Jones
,
+9 authors
L. Norton
The New England journal of medicine
2001
Corpus ID: 20066810
BACKGROUND The HER2 gene, which encodes the growth factor receptor HER2, is amplified and HER2 is overexpressed in 25 to 30…
Expand
Highly Cited
2000
Highly Cited
2000
Molecular portraits of human breast tumours
C. Perou
,
T. Sørlie
,
+15 authors
D. Botstein
Nature
2000
Corpus ID: 1280204
Human breast tumours are diverse in their natural history and in their responsiveness to treatments. Variation in transcriptional…
Expand
Highly Cited
2000
Highly Cited
2000
Group
P. F. Kauff
2000
Corpus ID: 218773023
Perhaps I am too concrete, too American in my way of thinking, but I need a level of accessibility that Claudio Neri 's book…
Expand
Highly Cited
1998
Highly Cited
1998
Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies.
J. Lazarou
,
B. Pomeranz
,
P. Corey
JAMA
1998
Corpus ID: 29939930
OBJECTIVE To estimate the incidence of serious and fatal adverse drug reactions (ADR) in hospital patients. DATA SOURCES Four…
Expand
Review
1998
Review
1998
Doxorubicin-induced cardiomyopathy.
P. Singal
,
N. Iliskovic
The New England journal of medicine
1998
Corpus ID: 39935547
Doxorubicin (Adriamycin) has been used in oncologic practice since the late 1960s. It held promise as a powerful drug in the…
Expand
Highly Cited
1981
Highly Cited
1981
A method for estimating the probability of adverse drug reactions
C. Naranjo
,
U. Busto
,
+6 authors
D. Greenblatt
Clinical pharmacology and therapeutics
1981
Corpus ID: 29728085
The estimation of the probability that a drug caused an adverse clinical event is usually based on clinical judgment. Lack of a…
Expand
Highly Cited
1979
Highly Cited
1979
Risk factors for doxorubicin-induced congestive heart failure.
D. V. Von Hoff
,
M. Layard
,
+4 authors
F. Muggia
Annals of internal medicine
1979
Corpus ID: 22793191
Potential risk factors responsible for development of doxorubicin-induced congestive heart failure were examined through…
Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our
Privacy Policy
,
Terms of Service
, and
Dataset License
ACCEPT & CONTINUE